Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03922373
Other study ID # EY20170502
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 10, 2018
Est. completion date April 30, 2019

Study information

Verified date April 2019
Source CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact Kun Lou
Phone 0311-67808817
Email loukun@mail.ecspc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective to study the pharmacokinetic, safety and efficacy of Single-dose and multiple-dose of benzonatate in Chinese healthy male and female subjects.


Description:

Objective to study the pharmacokinetic, safety and efficacy of Single-dose and multiple-dose of benzonatate in Chinese healthy male and female subjects. The study was designed to be single-center, open, and parallel, there are 3 groups A, B, C, each group will be enrolled in 12 healthy adult subjects. Single-dose of pharmacokinetics will be carried out in group A and C, single-dose and multiple-dose of pharmacokinetics will be carried out in group B. Subjects in group A and C will be given benzonatate of 100mg and 400mg respectively, Subjects in group B will be given benzonatate of 200mg. Subjects in group A and C will be given benzonatate once after a 10-hour fast in the first day of the trail. Subjects in group B will be given benzonatate once after a 10-hour fast in the first day of the trail, and they will be given benzonatate thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate once after a 10-hour fast. After completing blood collection and safety inspection at the appropriate time points, subjects can leave the test center. The main pharmacokinetic parameters will be calculated, to fully reflect the characteristics of drug absorption, distribution, metabolism and excretion in human body. The main pharmacokinetic parameters include Tmax, Cmax, Css, AUC0-t, AUC0-∞, λz, t1/2, Vd/F, CL/F, and so on.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 30, 2019
Est. primary completion date February 27, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- 1. You should fully understand the testing content, process and adverse reaction. Freely given informed consent.

2. Male or Female ages 18 through 45 (include 18 and 45).

3. The male subjects weighed more than 50 kg, the female subjects weighed more than 45kg. Body Mass Index(BMI) between 18 and 28, BMI=Weight(kg)/Height2(m2).

Exclusion Criteria:

- 1. Allergy to benzonatate, allergic constitution (Allergic to a variety of medicines and foods).

2. Abnormal physical examination and abnormal vital signs, and have clinical significance.

3. Abnormal results of laboratory studies and have clinical significance. 4. Abnormal electrocardiogram and have clinical significance. 5. The hepatitis B surface antigen(HbsAg), hepatitis C antibody, HIV antibody and antigen, Treponema pallidum antibody(TP-Ab)were positive.

6. Patients with cardiovascular system, urinary system, digestive system, nervous system, respiratory system, mental or immunodeficiency diseases.

7. Dysphagia or with gastrointestinal history influencing drug absorption. 8. Patients with any diseases that increase the risk of bleeding (e.g. acute gastritis, duodenal ulcer, and so on).

9. Patients smoked more than 5 cigarettes a day in the first 3 months of screening 10. Alcohol breath test were positive (blood-alcohol concentration>0.0mg/100ml) , or have history of alcoholism (more than 14 units of alcohol every week, 1 unit is equal to 285ml of beer, 25ml of spririts, or 100ml of wine.

11. Drug abuse screening were positive by urinalysis, or have a history of substance abuse or taken drugs last 3 years.

12. Subjects (or his fere) have family planning in the next 3 months, or can't take effective contraceptive measures in the next 3 months.

13. Female subjects during lactation, the quantitative of ß-HCG exceed the upper limit of normal range.

14. Donate blood or massive blood loss (>450ml) in the first 3 months of screening.

15. Taken any drugs that can inhibit the activity of liver enzyme in the first 28 days of screening, or taken the inhibitor or inducer of CYP3A4, P-gp, Bcrp, such as Itraconazole, Ketoconazole, Dronedarone.

16. Taken any prescription drugs, OTC, vitamin products or Chinese herbal medicine in the first 14 days of screening.

17. Special diets (e.g. pitaya, mango, pomelo) or strenuous exercise in the first 14 days of screening, or other factors to influence drug absorption, distribution, metabolism and excretion.

18. Have attended clinical trial in the first 3 months of screening 19. The patient can't finish the study according to protocol requirements. 20. Acute disease or simultaneous medication between screening stage and the first time taking study drugs.

21. Have consumed any alcoholic or caffeinated food or beverage such as chocolate and coffee in the first 48 hours of taking the study drug.

22. Investigator believes other factors not suitable for testing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Group A: Benzonatate 100mg
Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
Group B: Benzonatate 200mg
Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
Group C: Benzonatate 400mg
Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail

Locations

Country Name City State
China Cspc Nbp Pharmaceutical.Co.Ltd Shijiazhuang Hebei

Sponsors (1)

Lead Sponsor Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tmax Time to peak day 1 and day 4
Primary Cmax peak plasma concentration day 1 and day 4
Primary t1/2 elimination half-life time day 1 and day 4
Primary AUC0-t Area under the plasma concentration versus time curve from the medication to the last time the concentration can be measured day 1 and day 4
Primary AUC0-8 Area under the plasma concentration versus time curve from the medication extrapolate the infinity time day 1 and day 4
Primary CL/F elimination ratio day 1 and day 4
See also
  Status Clinical Trial Phase
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Not yet recruiting NCT04064333 - Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care N/A
Recruiting NCT02482818 - Efficacy of Pregabalin on Chronic Cough Phase 1/Phase 2
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Active, not recruiting NCT02065440 - The Effect of Ebastine/Pseudoephedrine on Subacute Cough N/A
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Terminated NCT00668317 - Bronchial Hyper-responsiveness in Reflux Cough Phase 3
Completed NCT00353951 - An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care N/A
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Recruiting NCT05115097 - AI Evaluation of COVID-19 Sounds (AI-EChOS)
Recruiting NCT04457011 - Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children Phase 2
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT05570539 - Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation Phase 1
Completed NCT03999203 - A Cross-sectional Study to Measure Cough in Severe Asthma N/A
Active, not recruiting NCT05479929 - Work of Breathing Assessment in Triage Scale
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A
Completed NCT02572375 - Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study Phase 1